ArticleRSC advances2020
Cytotoxic effect of green silver nanoparticles against ampicillin-resistant
Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges.Frontiers in microbiology · 2026Pooled it
- Biosynthesis of Silver Nanoparticles Using Brevibacillus parabrevis OW4: Optimization, Characterization, Antibacterial and Antibiofilm Applications.Applied biochemistry and biotechnology · 2026Article
- Antimicrobial and Cytotoxic Activities of Biogenic Nanoparticles Produced by Cyanobacteria.Chembiochem : a European journal of chemical biology · 2026Review
- Biofilms Exposed: Innovative Imaging and Therapeutic Platforms for Persistent Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Is 'Green' Gold and Silver Nanoparticle Synthesis Environmentally Friendly?Nanomaterials (Basel, Switzerland) · 2025Review
- Green Silver Nanoparticles: An Antibacterial Mechanism.Antibiotics (Basel, Switzerland) · 2024Review
- Article
- Implications of silver nanoparticles forFrontiers in cellular and infection microbiology · 2024Article
- Silver/Graphene Oxide Nanostructured Coatings for Modulating the Microbial Susceptibility of Fixation Devices Used in Knee Surgery.International journal of molecular sciences · 2023Article
- Bioactive ZnO Nanoparticles: Biosynthesis, Characterization and Potential Antimicrobial Applications.Pharmaceutics · 2023Review
- Characterization and evaluation of the therapeutic benefits of pure and lanthanides mono- and co-doped zinc oxide nanoparticles.Saudi journal of biological sciences · 2023Article
- Green Synthesis of Hexagonal Silver Nanoparticles Using a Novel MicroalgaePharmaceutics · 2022Article
- Silver Nanoparticle-Based Combinations with Antimicrobial Agents against Antimicrobial-Resistant Clinical Isolates.Antibiotics (Basel, Switzerland) · 2022Article
- Multidrug-Resistant Bacterial Pathogens and Public Health: The Antimicrobial Effect of Cyanobacterial-Biosynthesized Silver Nanoparticles.Antibiotics (Basel, Switzerland) · 2022Article
- Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19.Infectious diseases and therapy · 2022Review
- Anticandidal Potential of Two Cyanobacteria-Synthesized Silver Nanoparticles: Effects on Growth, Cell Morphology, and Key Virulence Attributes ofPharmaceutics · 2021Article
- Biosynthesis, Characterization and Antibacterial Application of Novel Silver Nanoparticles against Drug Resistant PathogenicMolecules (Basel, Switzerland) · 2021Article
- Emerging Concern for Silver Nanoparticle Resistance inFrontiers in microbiology · 2021Review
- An Updated Review on Silver Nanoparticles in Biomedicine.Nanomaterials (Basel, Switzerland) · 2020Review
- Oxidative Stress and Apoptotic Responses Elicited byCancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the harmful effects and high spread of drug-resistant
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.